Indications for: LEQVIO
Adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C.
Limitations of Use:
The effect on cardiovascular morbidity and mortality has not been determined.
Give by SC inj into abdomen, thigh, or upper arm. Initially 284mg as a single inj, repeat at 3 months, and then every 6 months. Measure LDL-lowering effect as early as 30 days after initiation and anytime thereafter.
Do not inject into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation, skin infections). ESRD. Severe hepatic impairment. Pregnancy: avoid. Nursing mothers.
Small interfering RNA (siRNA).
Inj site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity, dyspnea.
Generic Drug Availability:
Single-dose prefilled syringe—1